IFI-M · CUB Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-01939 // MULTI-AXIS · IFI-M

CUB Tri-Axis Dominant-Primary Series III-IV

Mentha × piperita

Peppermint

Tier IIICUB Tri-Axis Dominant-Primary Series

Target Trait

1.95×

fold-change

Cooling-dominant tri-axis U+B modulated fold-change

Technical Specifications

SKU

SS-F-M3-01939

Genomic Edits

10

GC Content

46.5%

Construct Length

5,652 bp

Promoter System

T7/SP6 cell-free

Expression System

In-vitro cell-free

Host Strain

Cell-free

Receptor Target

TRPM8 + mGluR1 + TAS2R38 (suppression)

IFI Score

195

Pathway Edits

  • TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
  • mGluR1 pathway primary gene cluster for umami (IFI-U) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent CUB pathway operation
  • Cross-pathway regulatory circuit for cooling-dominant CUB triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, mGluR1, and TAS2R38 (suppression) pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CUB) with cross-pathway flux managementCell-free co-translation of multi-axis enzyme sets for in-vitro biochemical validation

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier III CUB triple-axis construct for advanced multi-modal sensory architecture combining cooling, umami, and bitter-attenuation axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$1499 · Tier III License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Multi-Axis · IFI-MAll Modalities